ESMO 2022 | What does the future hold for ADCs in breast cancer?

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, gives an overview of current developments in the field of antibody-drug conjugates (ADCs) for breast cancer. Multiple ADCs, such as the anti-HER3 patritumab deruxtecan, are in Phase I clinical trials. Novel innovations additionally include bispecific ADCs as well as claudin as a promising target for this class of drugs. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.